Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

CLL Society Sends a Comment Letter to the Centers for Medicare and Medicaid Services Urging Continued Coverage of COVID-19 Treatments

In science and medicine, information is constantly changing and may become out-of-date as new data emerge. All articles and interviews are informational only, should never be considered medical advice, and should never be acted on without review with your health care team.

In September 2022, CLL Society submitted comments to the Centers for Medicare & Medicaid (CMS) regarding the proposed rule intended to update Medicare payment policies under the Physician Fee Schedule. We advocated on behalf of the CLL / SLL community in support of continuing the existing policy to ensure COVID-19 monoclonal antibodies (such as Evusheld) and their administration costs under the Part B vaccine benefit continue to be covered. Even if/when COVID-19 monoclonal antibodies receive full FDA approval and/or the US Government’s Emergency Use Authorization declaration for such products is terminated.

Read our letter here.